Jiang HJ, Chang YH, Chen YH, et al. - Good tolerability as well as acceptable efficacy and outcomes were shown by low-dose lenvatinib in radioiodine-refractory differentiated thyroid carcinoma (RRDTC) patients.

• Lenvatinib 24 mg/day was almost intolerable for RRDTC patients, with high rates of dose reduction, interruption and discontinuation noted.

• This analysis involved 65 RRDTC patients treated with lenvatinib.

• Different doses of lenvatinib were started but finally maintained with a median dose of 10 mg/day within the first 3 months.

• Disease control rate 89.2% was achieved, including 24.6% partial response and 64.6% stable disease.

• Treatment dose offered a median progression-free survival (PFS) of 26.1 months with overall survival (OS) not reached yet; the 48-month PFS and OS rates were 35.6% and 54.3%, respectively.

• Dose reduction rate was 44.6%, dose interruption rate was 40.0%, drug discontinuation rate was only 3.1%; the dose was tolerable.

• Fewer high-graded adverse events occurred.